ArticleBMJ open2025
Swedish Prescribed Drugs and Health Cohort (SPREDH): cohort profile update.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Menopausal hormone therapy and risk of liver cancer in a Swedish population-based cohort study.Journal of the National Cancer Institute · 2026Article
- Peritonsillar abscess as a clinical sign of oropharyngeal cancer - a Swedish national cohort study.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe Swedish Prescribed Drugs and Health Cohort (SPREDH) is a population-based cohort based on merged data from four nationwide health data registers in Sweden. SPREDH provides opportunities to investigate how the use of various medications influences cancer risk, cancer prognosis and many other outcomes. The cohort was recently updated to include a longer follow-up, more patients and additional drugs.
participantsSPREDH currently includes 9 454 340 users of selected medications, who have been followed up for a total of 138 015 003 person-years from 1 July 2005 to 31 December 2024, that is, for up to 19½ years. FINDINGS TO DATE: SPREDH includes data from the Swedish Prescribed Drug Register, Patient Register, Cancer Register and Cause of Death Register. Available data include participants' characteristics, use of medication, healthcare utilisation, diagnoses (including detailed information on cancers), surgical procedures and dates and causes of death. The original version of SPREDH has been used for 10 original studies published in scientific journals, primarily in the fields of gastroenterology and oncology. The updated version of SPREDH includes 1 382 698 participants who have developed a cancer during the follow-up. FUTURE PLANS: The newly updated and extended version of SPREDH enables studies with a wide range of study designs and hypotheses, especially pharmacoepidemiological studies evaluating how the use of certain medications affects the risk and prognosis of cancer and other diseases. It also allows for comparative research across classes of medications, as well as investigations of drug utilisation, safety and effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.